FORT LAUDERDALE, FL / ACCESSWIRE / November 11, 2022 / The lights seemed to shine bright on Liquivida at the first-ever IV BizBash last month in Orlando where Samael Tejada, president and founder, announced a round of revamped safety mechanisms and protocols for IV therapy clinics to implement across the United States.
While more IV providers pop up across state lines offering concierge in-home services and mobile IV's at events or on the go, industry leaders aim to standardize the way medical professionals administer IV therapy solutions in a wide range of settings. At the conference, medical entrepreneurs responded with hunger, determined to learn best practices from companies operating knee deep with great success in the space.
Sam is one of those pioneering individuals. But unlike others, he is a retired firefighter paramedic and self-made entrepreneur known by many as the creator of Liquivida's IV kits and vial packets, which make administering IV therapy services simple, safe, and more compliant than sourcing independently through a pharmacy. He started the company nine years ago at the age of 26 when the industry had very little backing or support and now he's found himself working with top-tier healthcare attorneys such as Jeff Cohen and the American IV Association (AIVA) to promote self regulation.
His idea to elevate safety and compliance started with the inception of Liquivida's proprietary all-inclusive IV infusion kits, which come prepared with everything you need to deliver optimal doses of vitamins, minerals, and amino acids into the bloodstream in the most safe and effective way possible. Liquivida IV drips and vial packets are sourced and packaged at a 503B pharmacy and protect consumers by ensuring a preservative-free single dose vial is used each and every time, taking the guesswork out so providers can focus on what actually matters: patient satisfaction and better healthcare outcomes.
For medical providers, efficacy and reliability are major contributing factors to business success. It's what keeps clients coming back, making IV therapy a regular part of their health regimen. Liquivida has been prioritizing these factors so clinics can remain compliant and offer the best to their clients. It also gives practitioners an extra layer of credibility as more consumers demand increased attention to quality products as well as better protocols and equipment at these facilities.
But lately, Liquivida is taking on a much different stance on safety beyond the box. Since the conference, Sam has been invited to educate a growing population of medical professionals who genuinely want to grow their IV therapy business the right way. He is advising that eager entrepreneurs move away from a "juice bar" commercialized approach and instead implement a model where IV therapy is used as functional medicine. He believes an IV business must focus on helping people address underlying health problems, such as autoimmune issues, chronic fatigue, and vitamin deficiencies.
On stage, Sam sat alongside top industry CEOs, including Jim Donnelly of Restore Hyper Wellness and Johnny Webber of Dripbar, where he reinforced the need for quality equipment and better protocols to administer an IV in the most sterile way possible. Some of these safety mechanisms are already included in each of Liquivida's IV kits and franchise models with things like micron filters inside of dispensing needles, medical grade refrigerators for storing sterile nutrients, ISO5 hood systems, videos and visual step-by-step instruction guides on how to prepare and administer an IV bag the correct way.
Liquivida offers two distinct franchise models. The first allows a medical provider to open an integrated Liquivida Lounge inside of an existing medical office or MedSpa adding an additional income stream to practitioners offering other complementary services. The second option is the Liquivida Wellness Center which is a storefront retail model, which allows business savvy franchise owners to sell a wider range of products and services such as medical aesthetics, sexual health, weight loss, hormone replacement therapy, and more under a recognizeable and respected brand that's built on trust. Both options come with a strict set of safety standards and compliance measures so that consumer safety and provider confidence remain a key part of the customer experience. This is especially important as less-seasoned medical professionals begin to enter this lucrative and desirable segment in the alternative medicine space, which is focused on keeping people healthy in the first place by targeting cellular health.
Over the next set of months, Sam will be seen speaking on safety, compliance, and better patient outcomes in various podcasts and at the American MedSpa Association (AmSpa) conference in February 2023. He will speak about how Medspa owners can start offering IV therapy safely to meet the growing demand from customers who seek a better quality of life.
Liquivida Lounge started as a concept at a Coconut Creek medical spa in 2013 with partners Dr. Leo Reyes and Dr. Howard Newman, and grew to be much bigger because people now prefer alternative medicine solutions to live longer, healthier lives.
Company: Liquivida Name: Emmanuel Trenche, MBA Address: Fort Lauderdale, Florida Email: emmanuel@liquivida.com
View source version on accesswire.com: https://www.accesswire.com/725198/Sam-Tejada-of-Liquivida-Announces-New-Safety-Protocols-Impacting-the-IV-Industry-at-First-IV-Conference
BTIG upgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Neutral to Buy with a price target of $27. The analyst writes that to Aerovate's benefit, Gossamer Bio Inc's (NASDAQ: GOSS) TORREY Phase 2 results validated dry powder inhaled (DPI)-administered TKIs in pulmonary arterial hypertension (PAH) as a safe and technically viable approach. But Gossamer's DPI seralutinib does not look like a competitive disease-modifying therapy in PAH, with a PVR reduction of only 14% in the overall study popu
Investors and analysts were unimpressed by trial results on the company's combination therapy to treat non-small cell lung cancer.
Investing in small-cap stocks can be very risky. Let's consider two small-cap stocks that carry above-average risk but that could soar as early as next year if things work out: Bluebird Bio (NASDAQ: BLUE) and Krystal Biotech (NASDAQ: KRYS). Bluebird Bio is a biotech that seeks to develop gene-editing treatments for rare illnesses.
Mirati said almost half of patients responded to its lung cancer regimen, but MRTX stock crashed on questions about its market opportunity.
Only last week, the company was warned about its stock price; this week it's looking at putting a premium on the price of its second FDA-approved drug.
Her friend and co-star John Travolta called her one of the "most special relationships I’ve ever had."
Consider, for instance, Editas Medicine (NASDAQ: EDIT) and BioXcel Therapeutics (NASDAQ: BTAI). Let's consider why Editas Medicine and BioXcel Therapeutics are worth keeping an eye on right now, and whether the potential rewards of investing in these companies outweigh the risks. The company is down by 61% this year, a terrible performance it partly owes to market-wide troubles.
Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.
“Respiratory infections are generally more common in winter, partly because viruses survive for longer in colder conditions, thereby increasing your chances of coming into contact with them,” says Andrew Easton, Professor of Virology at Warwick University. “People also tend to spend more time indoors during the winter months, increasing the chances of catching something.”
A for-profit California company saw windfall dividend — and patients scrambled for care, a CBS News investigation found.
Mirati Therapeutics Inc (NASDAQ: MRTX) announced preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort of adagrasib combined with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in previously untreated metastatic lung cancer patients, harboring a KRASG12C mutation. Early data shows that a combination treatment demonstrated promising preliminary clinical activity across all PD-L1 subgroups with an objective response rate (ORR) of 49%, with a manageable safety pr
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
More than half of the calories consumed by Americans come from this high-risk food group, which is associated with cognitive decline, cancer and heart disease
(Bloomberg) -- Verve Therapeutics Inc. shares fell the most in five months, pulling down shares of rival drugmakers, after the biotechnology company said US regulators requested additional information before allowing a test of its gene therapy to begin. Most Read from Bloomberg‘Huge, Missing and Growing:’ $65 Trillion in Dollar Debt Sparks ConcernStocks Hit by Fed-Hike Jitters as US Yields Surge: Markets WrapRussia Blames Ukraine for Blasts at Bases That Damaged WarplanesElon Musk’s Impossible E
The data presented for Eisai and Biogen’s drug wasn’t convincing enough to settle a debate among experts, but investors are betting on commercial success anyway.
SimpleImages / GettyThe fight against COVID seems to have fallen into a ping-ponging rhythm at this point, where every step forward seems undercut by one backward. Vaccines are available, and hospitalization rates have fallen dramatically from previous peaks. But just a sliver of eligible Americans have received the most recent bivalent shot, and the specter of a new, somehow worse variant looms large in our collective psyche. Elsewhere, such as in China, we seem to be losing ground to the virus
(Bloomberg) -- China is set to announce a further relaxation of Covid control measures as soon as today — including allowing some infected people to home quarantine as a nationwide policy, and reining in unnecessary testing — according to people familiar with the matter, as the government continues to quickly ease its zero-tolerance strategy amid growing public discontent. Most Read from BloombergTrump Companies Are Convicted in NY Criminal Tax Fraud TrialWall Street Goes Risk Off as Bank CEOs S
Novartis' (NVS) phase III PSMAfore study evaluating Pluvicto for treating patients with PSMA-positive metastatic castration-resistant prostate cancer meets primary endpoint.
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today significant results from the study of Onternabez combined with Favipiravir against ARDS (acute respiratory distress syndrome), Sepsis, and COVID-19 through PREPAiRE, an AI (Artificial Intelligence) powered platform which purposely integrates target identification, validation, lead discovery optimization, drug synthesis, and preclin
The actress ended up losing some of her hair during chemotherapy, and now she's celebrating its regrowth